Nektar Therapeutics (NASDAQ:NKTR) Analyst Rating Consensus

Nektar Therapeutics (NASDAQ:NKTR) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 1.38 by 8 Brokerage Firm. 7 Wall Street Firms have rated the stock as a strong buys. A sell rating was given by 1 analyst.

Nektar Therapeutics (NASDAQ:NKTR): The stock price is expected to reach $ 17.67 in the short term. The number of analysts agreeing with this consensus is 6. The higher estimate for the short term price target is at $20 while the lower estimate is at $14. The standard deviation of the price stands at $2.42.

Nektar Therapeutics (NASDAQ:NKTR) witnessed a decline in the market cap on Tuesday as its shares dropped 1.51% or 0.23 points. After the session commenced at $15.28, the stock reached the higher end at $15.49 while it hit a low of $14.89. With the volume soaring to 906,292 shares, the last trade was called at $14.98. The company has a 52-week high of $17.55. The company has a market cap of $2,041 million and there are 136,262,720 shares in outstanding. The 52-week low of the share price is $9.16.

Nektar Therapeutics has dropped 0.47% in the last five trading days, however, the shares have posted positive gains of 8.24% in the last 4 weeks. Nektar Therapeutics is up 15.5% in the last 3-month period. Year-to-Date the stock performance stands at -11.1%.

Nektar Therapeutics is a clinical-stage biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. The Companys pipeline is comprised of drug candidates for therapeutic areas, including oncology, pain, anti-infectives, and immunology. The Companys research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient. Its polymer chemistry platform is being used to create specialized therapeutics, including small molecule oral and parenteral drugs, proteins, peptides and antibody fragments.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.